Insider Transactions in Q1 2025 at Lexeo Therapeutics, Inc. (LXEO)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Richard Nolan Townsend Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,326
-1.93%
|
$17,304
$4.41 P/Share
|
|
Feb 19
2025
|
Jenny Robertson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,101
-3.5%
|
$8,404
$4.41 P/Share
|
|
Feb 19
2025
|
Eric Adler Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,359
-3.34%
|
$9,436
$4.41 P/Share
|
|
Feb 19
2025
|
Tai Sandi See Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,486
-2.68%
|
$5,944
$4.41 P/Share
|
|
Jan 17
2025
|
Kyle Rasbach Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,875
+50.0%
|
-
|
|
Jan 07
2025
|
Eric Adler Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+38.25%
|
-
|
|
Jan 07
2025
|
Tai Sandi See Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,750
+41.17%
|
-
|
|
Jan 07
2025
|
Jenny Robertson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,250
+37.66%
|
-
|
|
Jan 07
2025
|
Jose Manuel Otero Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,250
+31.34%
|
-
|
|
Jan 07
2025
|
Richard Nolan Townsend Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
103,750
+31.61%
|
-
|